OBJECTIVES: New treatments registered in mCRPC are expected to alter the way patients are currently treated. It is hence essential for developers of any new treatment not only to position it within the current therapeutic landscape, but also to anticipate what this landscape will resemble at time of launch. To address this issue, we developed a modeling tool that recast a new treatment’s value into the evolving therapeutic landscape. METHODS: We conducted a literature review of existing health economic models in mCRPC, including recent HTA reports and conference abstracts.  Technical and contextual elements were leveraged to build a flexible prototype economic model for new treatments.  The model encompasses disease management from asymptomatic mCRPC to patient’s death. It aims at describing the future management of mCRPC in including the current way patients are treated and the following innovative features: flexibility to alter the target population definition and size and to add new therapies. New therapies’ effectiveness and their expected positioning within the treatment pathway of mCRPC patients are assessed through the model. RESULTS: We have created a dynamic prototype model to position new options in the current and future therapeutic landscape for treatment of mCRPC in Europe. Economic models identified in literature were addressing specific reimbursement questions and were not flexible enough to be re-used for our purpose of assessing therapeutic landscape evolution. However, some technical elements on costs and effectiveness could be leveraged for our model.  The tool itself enabled to identify information gaps: epidemiology and real-life data were missing for some new treatments. These could be simulated and introduced in our easily-actualizable tool. CONCLUSIONS: An actualizable modeling and simulation tool was developed in mCRPC.  This tool enables dynamic identification of the best public health and economic outcomes out of a new potential therapeutic alternative.